Geographic and Temporal Trends of Transmitted HIV-1 Drug Resistance Among Antiretroviral-Naïve Subjects Screening for Two Clinical Trials in North America and Western Europe

REFERENCES

• Hogg RS, Yip B, KuIly C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretro-viral regimens. Can Med Assoc J. 1999;160(5):659–665.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in prevent-ing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483):378–384.
   PubMed Web of Science ®Google Scholar
• Daar ES, Richman DD. Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses. 2005;21(5):343–357.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of HIV-1 protease inhibitor-containing regimen: antiviral activity and correla-tion of baseline phenotypic drug susceptibility. J Infect Dis. 1999;179:1375–1381.
   PubMed Web of Science ®Google Scholar
• Zolopa AR, Shafer RW, Warlord A, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med. 1999;131:813–821.
   PubMed Web of Science ®Google Scholar
• Little SJ, Nolte S, Routy JP, et al. Antiretroviral-drug resis-tance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385–394.
   PubMed Web of Science ®Google Scholar
• Peuchant O, Thiebaut R, Capdepont S, et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS. 2008;22(12):1417–1423.
   PubMed Web of Science ®Google Scholar
• Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother. 2007;59:1047–1056.
   PubMed Web of Science ®Google Scholar
• Truong HML, Klausner JD, Hecht FM, et al. Reduced levels of primary resistance to nRTIs in San Francisco is discern-able using two independent sentinel populations. Antivir Ther. 2006;11:5115.
   Web of Science ®Google Scholar
• Smith D, Moini M, Pesano R, et al. Clinical utility of HIV standard genotyping among antiretroviral-naIve indi-viduals with unknown duration of infection. Clin Infect Dis. 2007;44:456–458.
   PubMed Web of Science ®Google Scholar
• Ross LL, Florance A, Wine B, et al. Prevalence of HIV-1 drug resistance-associated mutations in a large cohort of antiretroviral therapy (ART) naïve HIV-infected indi-viduals in the United States from 2000-2004. Antivir Ther. 2006;11:5119.
   Web of Science ®Google Scholar
• Martinez-Picado J, Gutierrez C, de Mendoza C, et al. Surveillance of drug resistance and HIV subtypes in newly diagnosed patients in Spain during 2004. Antivir Ther. 2005;10:S137.
   Google Scholar
• Kucherer C, Poggensee G, Korn K, et al. High level of resistance HIV-1 in newly diagnosed patients both with documented seroconversion and with unknown date of infection. In: Program and abstracts of the Fourth European HIV Drug Resistance Workshop; March 29–31, 2006; Monte Carlo, France. Abstract 10.
   Google Scholar
• Oette M, Kaiser R, Daumer M, et al. Trends of primary drug resistance in chronically HIV-infected patients in Germany, 2001-2005. Antivir Ther. 2006;11:S125.
   PubMed Web of Science ®Google Scholar
• Wensing AMJ, van de Vijver DA, Angarano G, et al. Preva-lence of drug-resistant HIV-1 variants in untreated indi-viduals in Europe: implications for clinical management. J Infect Dis. 2005;192:958–966.
   PubMed Web of Science ®Google Scholar
• Agwale SM, Zeh C, Paxinos E, et al. Genotypic and pheno-typic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naïve Nigerian patients. AIDS Res Hum Retroviruses. 2006;22:22–26.
   PubMed Web of Science ®Google Scholar
• Vidal N, Mulanga C, Bazepo S, et al. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses. 2006;22:202–206.
   PubMed Web of Science ®Google Scholar
• Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288(2):181–188.
   PubMed Web of Science ®Google Scholar
• Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Trans-mission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis. 1997;175(6):1502–1506.
   PubMed Web of Science ®Google Scholar
• Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther. 2004;9(5):695–702.
   PubMed Web of Science ®Google Scholar
• Schuurman R, Demeter L, Reichelderfer P, et al. Worldwide evaluation of DNA sequencing approaches for identifica-tion of drug resistance mutations in the human immunode-ficiency virus type 1 reverse transcriptase. J Clin Micro biol. 1999;37:2291–2296.
   PubMed Web of Science ®Google Scholar
• Schuurman R, Brambilla D, de Groot T, et al. Underestima-tion of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses. 2002;18:243–248.
   PubMed Web of Science ®Google Scholar
• Metzner KJ, Rauch P, Walter H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconvert-ers. AIDS 2005;19:1819–1825.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Li J-F, Brant A, et al. Multi-drug resistant HIV-1 are transmitted more frequently than current esti-mates. Antivir Ther 2005;10:S124.
   Google Scholar
• Johnson J, Li JF, Brant A, et al. Sensitive drug-resistance testing reveals a greater prevalence of transmitted multi-drug-resistant HIV-1 than previously estimated. In: Pro-gram and abstracts of the 14th Conference on Retrovi-ruses and Opportunistic Infections; February 5–8, 2006; Denver, CO. Abstract 642.
   Google Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15(4)119–125.
   Google Scholar
• Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance sur-veillance. AIDS. 2007;21(2):215–223.
   PubMed Web of Science ®Google Scholar
• Cameron DW, da Silva BA, Arribas JR, et al. A 96-week comparison of lopinavir-ritonavir combination therapy fol-lowed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008;198(2):234–240.
   PubMed Web of Science ®Google Scholar
• Gathe J, da Silva BA, Cohen DE, et al. A once daily lopinavir/ritonavir based regimen is non-inferior to twice daily dosing and results in similar safety and tolerability in antiretroviral naïve subjects through 48 weeks. JAIDS. 2009; 50(5):474–1481.
   Google Scholar
• Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005;331(7529):1368.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves nevirap-ine to treat HIV. June 24,1996. Available at: http://www.fda.gov/bbs/topics/ANSWERS/AN500742.html. Accessed February 3, 2008.
   Google Scholar
• Viramune® approved by European Commission for treat-ment of HIV. Boehringer Inge!helm Press Release. February 10, 1998. Available at: http://www.boehringer-ingelheim.com/hiv/archive/adetail.asp?ID=56. Accessed February 3, 2008.
   Google Scholar
• AIDS epidemic update. Joint United Nations Program on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2007. December 2007; 1–50. Available at: http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf. Accessed February 1,2009.
   Google Scholar
• de Mendoza C, Rodriguez C, Eiros JM, et al. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis. 1995;21:556–560.
   PubMed Web of Science ®Google Scholar
• Lohse N, Obel N, Kronborg G, et al. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther. 2006;11:591–600.
   PubMed Web of Science ®Google Scholar
• European Public Assessment Reports (EPARs) for autho-rized medicinal products for human use, Norvir. European Medicines Agency (EMEA). August 26,1996. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/norvir/norvir.htm. Accessed February 8, 2009.
   Google Scholar
• Turner D, Brenner B, Routy JP, et al. Diminishing represen-tation of HIV-1 variants containing select drug-resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr. 2004;37:1627–1631.
   PubMed Web of Science ®Google Scholar
• Corvasce S, Violin M, Romano L, et al. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir Ther. 2006;11:329–334.
   PubMed Web of Science ®Google Scholar
• Nicastri E, Sarmati L, d'Ettore G, et al. Replication capac-ity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol. 2002;69:1–6.
   Web of Science ®Google Scholar
• Leigh Brown AJ, Frost SD, Mathews C, et al. Transmis-sion fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis. 2003;187:683–686.
   PubMed Web of Science ®Google Scholar
• Bezemer D, de Ronde A, Prins M, et al. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther. 2006;11:173–178.
   PubMed Web of Science ®Google Scholar
• Taylor BS, Sobieszczyk ME, McCutchan FE, et al. The challenge of HIV-1 subtype diversity. New Engl J Med. 2008;358:1590–1602.
   PubMed Web of Science ®Google Scholar
• Palmer S, Boltz V, Maldarelli F, et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS. 2006:20:701–710.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3,2008; 1–139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultsandAdolescentGL.pdf. Accessed February 1,2009.
   Google Scholar
• European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe. October 2008; 1–17. Available at: http://www.eacs.eu/guide/1_Treatment_of_HIV_Infected_Adults.pdf. Accessed February 1, 2009.
   Google Scholar
• Beddows S, Galpin S, Kazmi SH, et al. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resis-tance against HIV type 1 group M subtypes. J Med Virol. 2003;70:337–342.
   PubMed Web of Science ®Google Scholar
• Tong CYW, Mullen J, Kulasegaram R, et al. Genotyping of B and non-B subtypes of human immunodeficiency virus type 1. J Clin Microbiol. 2005;43(9):462–467.
   PubMed Web of Science ®Google Scholar
• Pandit A, Mackay WG, Steel C, et al. HIV-1 drug resis-tance genotyping quality assessment: results of the ENVA7 genotyping proficiency programme. J Clin Virol. 2008;43:401–406.
   PubMed Web of Science ®Google Scholar